

AMENDMENTS TO THE CLAIMS

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently amended) An isolated human RL5 polypeptide comprising ~~a polypeptide~~ having the amino acid sequence of SEQ ID NO: 2, or the amino acid sequence of 29-213 of SEQ ID NO: 2 ~~its conservative variants, its active fragments, and its active derivatives.~~

2. (Currently amended) The polypeptide of Claim 1 wherein the polypeptide is consisting of selected from the group consisting of:

(a) ~~a polypeptide consisting of the amino acid sequence of 1-213 of SEQ ID NO: 2 or the amino acid sequence of 29-213 of SEQ ID NO: 2;~~

(b) ~~the polypeptide having the function of binding to NKG2D and derived from the polypeptide of (a) by substituting, deleting or adding one or more amino acid residues in the amino acid sequence of 1-213 of SEQ ID NO: 2 or the amino acid sequence of 29-213 of SEQ ID NO: 2.~~

3. (Currently amended) An isolated polynucleotide which is ~~comprising a nucleotide sequence sharing at least 70% homology to a nucleotide sequence~~ selected from the group consisting of:

(a) a nucleotide sequence encoding the RL5 polypeptide defined in Claim 1;

(b) the polynucleotide complementary to the nucleotide sequence of (a).

4. (Currently amended) The polynucleotide of Claim 3 which encodes a polypeptide comprising the amino acid sequence of the amino acid sequence of ~~1-213 of SEQ ID NO: 2 or the amino acid sequence of 29-213 of SEQ ID NO: 2.~~

5. (Original) The polynucleotide of Claim 3 which is selected from the group consisting of

(a) the nucleotide sequence of 85-639 of SEQ ID NO: 1;

(b) the nucleotide sequence of 1-639 of SEQ ID NO: 1; and

(c) the nucleotide sequence of 1-720 of SEQ ID NO: 1.

6. (Original) A vector containing the polynucleotide of Claim 3.

7. (Original) A genetically engineered host cell comprising the vector of Claim 6.

8 . (Currently amended) A method for producing RL5 protein, which comprises:

(a) culturing the host cell of Claim 7 under the expression conditions, thereby expressing RL5 protein;

(b) isolating RL5 protein from the culture.

9. (Original) An antibody specifically bound with the RL5 polypeptide of Claim 1.

10. (Currently amended) A method for detecting the presence of RL5 protein in a sample comprising contacting the sample with an antibody specifically against RL5 protein, thereby forming an antibody complex, and observing the formation of antibody complex which indicates the presence of RL5 protein in the sample.

11. (New) A pharmaceutical composition comprising a safe and efficient amount of RL5 antagonist and a pharmaceutically acceptable carrier.

12. (New) The pharmaceutical composition of Claim 11 wherein the RL5 antagonist is an antibody against RL5 protein or an antisense nucleotide sequence of RL5 gene.